ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

zeprumetostat

Also written as “SHR2554”, “TLN-254” and “SHR2554 Tablets”.

Its studies are mostly in Lymphoma · Neoplasms · Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 2 companies.

Drug pageZeprumetostat: every studyAll 39 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 5, 202317 company-led studies, 7 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine166 open or runningphase 3since Nov 5, 2023Jul 10, 2018Apr 2027phase 2 · NCT06368167
Treeline Biosciencesits history only11 open or runningphase 1since Dec 10, 2024Dec 10, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 10, 2018.

  1. Apr 1, 2020Phase 1 study in Healthy Adult SubjectsNCT04335266 · 20 enrolled · China
  2. Sep 24, 2020Phase 1 study in HealthyNCT04577885 · 18 enrolled · China
  3. Oct 27, 2020Phase 1 study in Healthy Adult SubjectsNCT04627129 · 18 enrolled · China
  4. Sep 9, 2021Phase 1 study in LymphomaNCT05049083 · 28 enrolled · China
  5. Oct 20, 2022Phase 1 study in NeoplasmsNCT05592262 · 20 enrolled · China
  6. Dec 15, 2022Phase 1 study in NeoplasmsNCT05661591 · 18 enrolled · China
  7. Aug 20, 2023Phase 1 study in LymphomaNCT06010680 · 6 enrolled · China
  8. Oct 17, 2023Phase 1 study in NeoplasmsNCT06093945 · 20 enrolled · China
  9. Nov 5, 2023Phase 3 study in RecurrenceNCT06122389 · 130 planned · China
  10. Dec 8, 2023Phase 2 study in Lymphoma, T-Cell, PeripheralNCT06173999 · 100 planned · China
  11. Apr 11, 2024Phase 2 study in Lymphoma, FollicularNCT06368167 · 105 planned · China
  12. Aug 11, 2024Named zeprumetostatINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SHR2554, TLN-254
  13. Jul 29, 2025Phase 2 study in Stomach NeoplasmsNCT07102901 · 351 planned · China
  14. Sep 9, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220 · 200 planned · China
  15. Nov 13, 2025Phase 2 study in Prostatic NeoplasmsNCT07230106 · 218 planned · China

Ahead

  1. Apr 2027Primary completion: phase 2 study in Lymphoma, FollicularNCT06368167
  2. Dec 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07102901
  3. Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07175220
  4. Dec 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT07230106

TargetBeta

EZH2 →read by rule
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule

Other programs on EZH2

ProgramCompanyFurthest phaseStudies
mevrometostatPfizerphase 37
TR115ruletarapeutics-science-incphase 33
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

All 16 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07230106Prostatic Neoplasms · China2RecruitingDec 2028218
NCT07175220Carcinoma, Non-Small-Cell Lung · China2RecruitingOct 2028200
NCT07102901Stomach Neoplasms · China2RecruitingDec 2027351
NCT06368167Lymphoma, Follicular · China2Not yet recruitingApr 2027105
NCT06173999Lymphoma, T-Cell, Peripheral · China2RecruitingDec 31, 2025100
NCT06122389Recurrence · China3RecruitingMay 2026130
NCT06093945Neoplasms · China1CompletedNov 29, 202320
NCT06010680Lymphoma · China1CompletedNov 27, 20236
NCT05661591Neoplasms · China1CompletedMar 31, 202318
NCT05592262Neoplasms · China1CompletedDec 14, 202220
NCT05049083Lymphoma · China1UNKNOWNJan 6, 202228
NCT04627129Healthy Adult Subjects · China1CompletedOct 1, 202018
NCT04577885Healthy · China1CompletedAug 30, 202018
NCT04335266Healthy Adult Subjects · China1CompletedSep 9, 201920
NCT03741712Prostatic Neoplasms · China2TerminatedSep 30, 20199
NCT03603951Recurrence · China1UNKNOWNFeb 14, 2026272

How it is read

Names in the registry

  • “SHR2554”, 6 entries
  • “TLN-254”, 2 entries
  • “SHR2554 Tablets”, 2 entries
  • “SHR2554 Tablet”, 1 entry
  • “SHR2554; Chidamide analog tablets”, 1 entry

Codes read as this program: SHR2554.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.